Is Sana Biotechnology Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Sana Biotechnology Inc (SANA) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Sana Biotechnology Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Sana Biotechnology Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Sana Biotechnology Inc?

Muslim investors may consider investing in Sana Biotechnology Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Sana Biotechnology Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Sana Biotechnology Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Sana Biotechnology Inc updated?

The Shariah compliance status of Sana Biotechnology Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Sana Biotechnology Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Sana Biotechnology Inc?

You can check the latest Shariah compliance status of Sana Biotechnology Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

SANA Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 04, 2026

Report Source: 2025 Annual Report

Sana Biotechnology Inc. Stock Analysis SANA

United States Health Care Small Cap Report: 2025 Annual

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 142 full-time employees. The company went IPO on 2021-02-04. The company is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), oncology, and B cell mediated autoimmune diseases. The company develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline products include SC451 and UP421. SC451 is its HIP-edited product candidate for the treatment of type 1 diabetes. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. Its ex vivo cell engineering platform is focused on engineering hypoimmune cells that engraft, function, and persist in patients by evading immune rejection.

Key Statistics of Sana Biotechnology Inc (SANA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$2.96$3.11

Today's Open

$3.05

Volume

3.70M

P/E Ratio (TTM)

52 Week Range

$1.60$6.55

Market Cap

931.37M

Avg. Volume

4.41M

Dividend Yield

Financial Metrics & Statements of Sana Biotechnology Inc (SANA)

FAQ's for Sana Biotechnology Inc (SANA)

According to Musaffa’s Shariah screening methodology, Sana Biotechnology Inc (SANA) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.